[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hung Vuong Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100635951",false,"NCT07559357","OSC Co-culture for Rescue IVM of Human GV Oocytes","Effect of iPSC-Derived Ovarian Support Cell Co-culture on Rescue In Vitro Maturation of Human Germinal Vesicle Oocytes: A Randomized Sibling-Oocyte Controlled Trial","OSC-rIVM","Inclusion Criteria:\n\n* Women aged 18 to 45 years.\n* At least 2 GV oocytes retrieved in a single oocyte retrieval cycle.\n* Voluntary informed consent from the couple to participate in the study.\n* Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.\n\nExclusion Criteria:\n\n* Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE.\n* Use of donor gametes, including donor oocytes or donor sperm.\n* Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.","FEMALE","18 Years","45 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-center randomized sibling-oocyte controlled trial evaluates whether co-culture with induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) improves rescue in vitro maturation (r-IVM) outcomes of surplus germinal vesicle (GV) oocytes collected during routine IVF treatment. Eligible GV oocytes from each enrolled participant are allocated within participant in a 1:1 ratio to either conventional r-IVM or r-IVM with OSC co-culture. The primary outcome is the metaphase II (MII) maturation rate after 24 hours of culture. Secondary outcomes include fertilization rate, day 3 embryo formation, good-quality day 3 embryo rate, blastocyst formation, and good-quality blastocyst rate. All embryos generated in the study are for research purposes only and will not be used for clinical embryo transfer.",[27,28],"Oocyte Maturation","Infertility",[30,31,32,33,34,35,36,37],"Rescue in vitro maturation","r-IVM","Germinal vesicle oocyte","iPSC-derived ovarian support cells","OSC co-culture","Embryo development","IVF","Sibling-oocyte trial","NOT_YET_RECRUITING","2026-04-23",{"date":41,"type":42},"2026-04-30","ACTUAL",{"date":44,"type":21},"2026-06",{"date":46,"type":21},"2027-05",{"name":48,"class":49},"Hung Vuong Hospital","OTHER",1,{"id":52,"slug":4,"hasResults":10,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100592203","NCT06990373","Iron Status of Non-anemic Pregnant Women in First Trimester","Establishment of Reference Intervals for Iron Test Panel for Pregnant Women at Hung Vuong Hospital","Inclusion Criteria:\n\n* Pregnant women attending antenatal care, carrying a single live fetus.\n* Systolic blood pressure at the time of examination \\\u003C 140 mmHg.\n* Diastolic blood pressure at the time of examination \\\u003C 90 mmHg.\n* Body temperature at the time of examination between \\>35°C and \\\u003C37.5°C.\n* Hemoglobin ≥ 11 g\u002FdL\n\nExclusion Criteria:\n\n* History of diabetes mellitus, hypertension, hemoglobinopathies, leukemia, non-hematologic cancers, systemic lupus erythematosus, Gastrointestinal diseases (Celiac disease, Crohn's disease and ulcerative colitis, Gastric diseases or prior gastrointestinal surgery, Irritable bowel syndrome, etc).\n* Currently on gastric acid-suppressing medications: Proton pump inhibitors (e.g., Omeprazole, Lansoprazole, Esomeprazole...), H2 receptor antagonists (e.g., Ranitidine, Famotidine, Cimetidine...), Positive screening for Treponema pallidum, HBsAg, or HIV.\n* Use of stimulants or tobacco smoking.",true,{"count":59,"type":21},600,"1 Week","OBSERVATIONAL","This cross-sectional study aims to establish reference intervals for iron biomarkers-including serum iron, ferritin, total iron-binding capacity (TIBC), and transferrin saturation (TSAT)-in healthy pregnant women during the first trimester. Additionally, the study will investigate the current prevalence of non-anemic iron deficiency (NAID) in this population. By applying strict inclusion and exclusion criteria to eliminate potential confounding factors, the study seeks to provide a reliable baseline for evaluating iron status and early detection of iron deficiency without anemia among pregnant women.",[64,65,66],"Iron Deficiency (Without Anemia)","Reference Values","Iron Deficiency Without Anemia",[68,69,70,71],"NAID","IDWA","Iron deficiency","Pregnant","RECRUITING","2025-05-24",{"date":75,"type":42},"2025-05-30",{"date":77,"type":42},"2025-03-12",{"date":79,"type":21},"2025-08-30",{"name":48,"class":49},""]